Pyruvate as a Pivot Point for Oncogene-Induced Senescence  by Olenchock, Benjamin A. & Vander Heiden, Matthew G.
et al.; C4 Grasses Consortium. (2010). Science
328, 587–591.
Heckmann, D., Schulze, S., Denton, A., Gowik, U.,
Westhoff, P., Weber, A.P.M., and Lercher, M.J.
(2013). Cell 153, this issue, 1579–1588.Lindsey, H.A., Gallie, J., Taylor, S., and Kerr, B.
(2013). Nature 494, 463–467.
Raven, J.A., Cockell, C.S., and De La Rocha, C.L.
(2008). Philos. Trans. R. Soc. Lond. B Biol. Sci.
363, 2641–2650.Cell 15Sage, R.F., Sage, T.L., and Kocacinar, F. (2012).
Annu. Rev. Plant Biol. 63, 19–47.
von Caemmerer, S. (2000). Biochemical models of
leaf photosynthesis. Techniques in Plant Science.
(Collingwood, Australia: CSIRO Publishing).Pyruvate as a Pivot Point
for Oncogene-Induced Senescence
Benjamin A. Olenchock1,2,3 and Matthew G. Vander Heiden1,2,*
1Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
2The Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA
3The Division of Cardiovascular Medicine, Department of Medicine, The Brigham and Women’s Hospital, Harvard Medical School,
75 Francis Street, Boston, MA 02115, USA
*Correspondence: mvh@mit.edu
http://dx.doi.org/10.1016/j.cell.2013.06.001
Regulation of pyruvate fate is an important determinant of anabolic versus catabolic metabolism.
A new report in the journal Nature by Kaplon et al. suggests that driving pyruvate oxidation can
thwart tumor growth in BRAF-driven melanoma by inducing oncogene-induced senescence, a
finding that might be exploited therapeutically.Themetabolic fate of pyruvate plays a cen-
tral role inmetabolism that extendsbeyond
the choice between oxidative glucose
metabolism in themitochondriaandanaer-
obic fermentation of glucose in the cytosol.
Pyruvate sits at a crossroads of several
anabolicandcatabolicpathways(Figure1),
and pyruvate metabolism impacts many
aspects of cellular biochemistry, including
ATP generation, redox status, fuel selec-
tion, oxygen consumption, and biomass
production. A new study in Nature (Kaplon
et al., 2013) suggests that pyruvate meta-
bolism is critically important in the setting
ofmelanoma-associatedBRAFmutations.
The authors demonstrate that high rates of
mitochondrial pyruvate oxidation promote
oncogene-induced senescence (OIS), a
critical defense against tumor progression.
In the absence of additional cooper-
ating genetic alterations, oncogenic
mutations in BRAF cause growth arrest
in melanocyte neoplasias (Michaloglou
et al., 2005). This phenomenon of OIS is
accompanied by distinct phenotypic
characteristics and classically involves
activation of the p53 or RB signaling path-ways (Kuilman et al., 2010). Kaplon et al.
studied the metabolic effects of OIS
induced by mutant BRAFV600E in human
diploid fibroblasts. The authors demon-
strated that BRAFV600E-induced senes-
cent cells have increased pyruvate entry
into the mitochondrial tricarboxylic acid
(TCA) cycle through the pyruvate dehy-
drogenase complex (PDH). PDH flux is
regulated by the cell’s energetic, nutrient,
and redox status and via inhibitory phos-
phorylation mediated by PDH kinases
(Patel and Korotchkina, 2006). Increased
PDH activity in the senescent cells was
associated with decreased expression of
the PDH kinase 1 (PDK1) and increased
expression of the PDH phosphatase 2
(PDP2). Together, these transcriptional
changes results in less inhibitory phos-
phorylation of PDH and increased com-
plex activity.
Kaplon et al. provide evidence that
altered pyruvate metabolism might be a
direct mediator, rather than a conse-
quence, of OIS. By increasing expression
of PDK1 or decreasing expression of
PDP2, the authors show that activation ofPDH activity is required for OIS in
the setting of mutant BRAF expres-
sion. Forced PDK1 expression in
p53/;BRAFV600E neonatal melanocytes
was found to be sufficient to overcome
OIS and promote tumorigenesis. Con-
versely, knockdown of PDK1 impaired
the ability of human melanoma cell lines
to form tumors and led to regression of
established tumors generated from
these cells in immunocompromised mice.
Additionally, PDK1 knockdown was found
to sensitize BRAFV600E melanoma cell
lines to an analog of vemurafenib, a
BRAF inhibitor currently used in patients.
The findings of Kaplon et al. are certain
to stoke interest in targeting pyruvate
oxidation to treat melanoma. In this
regard, dichloroacetate (DCA) has
received attention as an inhibitor of PDK
and as a potential anticancer agent
(Michelakis et al., 2008). If DCAwere found
to synergize with BRAF inhibitors in a
manner similar to PDK1 knockdown, there
might be an opportunity for near-term pa-
tient benefit. The importance of PDK1
and PDP2, and by extension a role for3, June 20, 2013 ª2013 Elsevier Inc. 1429
Figure 1. Pyruvate Is a Critical Hub in the Metabolic Network,
Interfacing with Multiple Anabolic and Catabolic Pathways
A schematic is provided for how pyruvate links to metabolic pathways
including the mitochondrial TCA cycle, glycolysis, fatty acid synthesis,
nucleotide synthesis, and alanine production. Where malic enzyme lies in
relation to pyruvate metabolism is also shown. Kaplon et al. suggest that
oncogenic BRAFV600E brings about OIS by inducing PDP2 and suppressing
PDK1, which together lessen phosphorylation of the pyruvate dehydrogenase
complex (PDH), increase PDH flux, and favor catabolic metabolism. This state
is not conducive to cell proliferation.PDK inhibition, in other
models of OIS is less clear. In
a model of OIS involving
KRASG12V, the authors
demonstrated that PDHactiv-
ity was elevated under senes-
cence conditions, but the
change in PDH flux was not
due to alterations in PDK1 or
PDP2 expression, and large
changes in PDHphosphoryla-
tion were not observed.
Indeed, the regulation of
PDHcomplexactivity extends
beyond inhibitory phosphory-
lation, and other mechanisms
may limit pyruvate oxidation
in non-BRAF-driven tumors.
Additionally, the generaliz-
ability of increased PDH flux
causing senescence in other
models might be limited, as
senescence has been re-
ported after loss of the von
Hippel-Lindau (VHL) tumor
suppressor, a condition under
which high PDK1 expression
and low PDH flux would be
expected (Young et al., 2008;
Metallo et al., 2011).
The pyruvate ‘‘hub’’ has
been suggested as a drug
target for treatment of dis-
eases as wide ranging as
lactic acidosis, diabetes,
ischemic heart disease, and
cancer (see Roche and Hiro-masa, 2007 for review). By driving pyru-
vate to one fate over another, the entire
metabolic landscape of the cell can be
affected, in some instances achieving a
desirable therapeutic effect. Otto War-
burg’s observation that proliferating can-
cer cells do not oxidize all of their pyruvate
is illustrative here, as generation of
biomass from glucose is impossible if all
of the carbon is oxidized to CO2 in the
mitochondria. By extension, genetic or
pharmacologic manipulations that
increase pyruvate oxidation might shuttle
glucose carbons away from biosynthesis
pathways that are necessary for cell
growth and division. Recent work has1430 Cell 153, June 20, 2013 ª2013 Elsevierhighlighted the importance of nucleotide
metabolism (Aird et al., 2013) and malic
enzyme activity (Jiang et al., 2013) in
OIS. Whether these pathways are
affected by manipulating pyruvate fate to
induce OIS remains to be determined,
but one could speculate that alterations
in pyruvate metabolism might affect
NADPH generation through malic en-
zyme, perhaps limiting DNA synthesis
necessary for cell-cycle progression and
linking the findings of all three studies.
Cells adopt specific metabolic pro-
grams as a response to mutations and
environmental cues. Sorting out to what
extent changes in metabolism are causalInc.for biological phenomena
such as OIS is challenging,
particularly as the network ef-
fects of specific genetic or
pharmacologic manipulations
can be difficult to predict and
accurately measure. None-
theless, the findings of
Kaplon et al. contribute to
the mounting evidence that
metabolic programs might
be targeted to limit cancer
initiation and progression
and provide another example
of how coordinating flux
through anabolic and cata-
bolic pathways is necessary
for sustained cell prolifera-
tion.
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